Generational gains in cognitive capacity and dementia incidence rates in Western countries

Abstract Dementia incidence has been declining in Western societies for decades, but whether this reflects higher cognitive capacity entering old age, slower cognitive decline, or both remains unresolved. Analysing ~783,000 episodic memory assessments from ~219,000 individuals across five longitudinal cohorts, we find that later-born cohorts benefit from a double dividend: higher memory levels entering old age and slower rates of decline. The projected 20-year cohort advantage at age 80 is of sufficient magnitude to plausibly account for the observed 13% per-decade decline in dementia incidence reported in meta-analyses. Generational gains are disproportionately concentrated among the fastest-declining individuals, and are reflected in lower hippocampal atrophy rates in an independent sample. A formal bounding analysis shows that the double dividend is robust across a range of plausible period assumptions, consistent with environmental conditions operating across the lifespan having reshaped the architecture of human cognitive aging.

Authors

Institutions

Publication Details

Journal
Nature Medicine
Published
2026-11-17
DOI
https://doi.org/10.1038/s41591-026-04759-y
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Generational gains in cognitive capacity and dementia incidence rates in Western countries

Dídac Vidal-piñeiro A, Ole Jørgen Røgeberg, Anders M. Fjell, Gabriela Lunansky et al.
Nature Medicine
Dementia and Cognitive Impairment Research
article

Generational gains in cognitive capacity and dementia incidence rates in Western countries

Dídac Vidal-piñeiro A, Ole Jørgen Røgeberg, Anders M. Fjell, Gabriela Lunansky, Kristine Beate Walhovd, Edvard Grødem
article en

Abstract

Abstract Dementia incidence has been declining in Western societies for decades, but whether this reflects higher cognitive capacity entering old age, slower cognitive decline, or both remains unresolved. Analysing ~783,000 episodic memory assessments from ~219,000 individuals across five longitudinal cohorts, we find that later-born cohorts benefit from a double dividend: higher memory levels entering old age and slower rates of decline. The projected 20-year cohort advantage at age 80 is of sufficient magnitude to plausibly account for the observed 13% per-decade decline in dementia incidence reported in meta-analyses. Generational gains are disproportionately concentrated among the fastest-declining individuals, and are reflected in lower hippocampal atrophy rates in an independent sample. A formal bounding analysis shows that the double dividend is robust across a range of plausible period assumptions, consistent with environmental conditions operating across the lifespan having reshaped the architecture of human cognitive aging.

Nature Medicine
Oslo University Hospital (NO), University of Oslo (NO), Amsterdam University Medical Centers (NL), Ragnar Frisch Centre for Economic Research (NO), Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Foundation for the National Institutes of Health, Mayo Clinic, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Roche, Atlantic Philanthropies, U.S. Social Security Administration, Biogen, University of Southern California, Mayo Foundation for Medical Education and Research, Meso Scale Diagnostics, University of Michigan, BioClinica, Novartis Pharmaceuticals Corporation, McGill University, Fondation Brain Canada, Northern California Institute for Research and Education, Health Research Board, Government of the United Kingdom, GHR Foundation, Elsie and Marvin Dekelboum Family Foundation, An Roinn Sláinte, Government of Canada, National Institute for Health and Care Research, Department of Health and Social Care, European Commission, Commonwealth Scientific and Industrial Research Organisation, Trinity College Dublin, Eisai, Max-Planck-Gesellschaft, Universitetet i Oslo, Norges Forskningsråd, Schuler-Stiftung, Servier, Nasjonalforeningen for Folkehelsen, H. Lundbeck A/S, IXICO, National Institutes of Health, Genentech, Johnson and Johnson, Pfizer Canada, Avid Radiopharmaceuticals, Canadian Institutes of Health Research, Fonds de Recherche du Québec - Santé, Directorate-General for Employment, Social Affairs and Inclusion, Livsvitenskap, Universitetet i Oslo, National Institute on Aging, National Institute of Biomedical Imaging and Bioengineering, H2020 European Research Council, FP7 Ideas: European Research Council
Good health and well-being
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon